Related Experiment Video
Updated: Jan 1, 2026
Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
Published on: May 31, 2024
What Do We Know About Chagas Disease in the United States?
Susan P Montgomery1, Monica E Parise1, Ellen M Dotson1
1Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
Insights
Chagas disease, caused by Trypanosoma cruzi, impacts millions globally. In the U.S., 300,000+ chronic cases exist, necessitating research into local transmission and prevention.
Area of Science:
- Infectious Diseases
- Parasitology
- Public Health
Background:
- Chagas disease, caused by Trypanosoma cruzi, affects over 5 million people worldwide.
- Chronic infection can lead to severe cardiac and gastrointestinal complications.
- Transmission occurs via vectors, congenital routes, blood transfusion, and organ transplantation.
Purpose of the Study:
- To highlight the burden of Chagas disease in the United States, with an estimated 300,000 chronic cases.
- To address the need for research on domestic transmission risks and prevention strategies for Trypanosoma cruzi.
- To emphasize the necessity of improved healthcare provider awareness, diagnostic tools, and treatment availability.
Main Methods:
- Review of existing literature on Chagas disease epidemiology and transmission in the Americas.
- Analysis of estimated prevalence in the United States.
- Identification of knowledge gaps and areas for future research.
Main Results:
- Vector-borne transmission of Chagas disease is established in the Americas, including the southern U.S.
- While over 300,000 chronic cases are estimated in the U.S., locally acquired infections are rare (<30 documented).
- A sylvatic transmission cycle of Trypanosoma cruzi has been recognized in the U.S. for over a century.
Conclusions:
- There is a significant burden of chronic Chagas disease in the U.S. among individuals from endemic regions.
- Further studies are crucial to understand risks for local Trypanosoma cruzi transmission and develop effective prevention.
- Enhancing healthcare provider knowledge, diagnostic capabilities, and treatment access are vital for managing Chagas disease in the U.S.
Abstract:
Chagas disease, caused by the parasite Trypanosoma cruzi, affects more than 5 million people worldwide leading to serious heart and gastrointestinal disease in a proportion of chronically infected patients. Important modes of transmission include vector-borne, congenital, and via blood transfusion or organ transplant from an infected donor. Vector-borne transmission of Chagas disease occurs in the Americas, including the southern half of North America, where the specific vector insects (triatomines), T. cruzi, and infected reservoir mammalian hosts are found. In the United States, there are estimated to be at least 300,000 cases of chronic Chagas disease among people originally from countries of Latin America where Chagas disease is endemic. Fewer than 30 cases of locally acquired infection have been documented in the United States, although a sylvatic transmission cycle has been known to exist in this country for at least a century. Studies defining risks for locally acquired infection and effective prevention strategies are needed to help prevent domestic transmission of T. cruzi To help address Chagas disease in the United States, improved health-care provider awareness and knowledge, better tools for screening and diagnosing patients, and wider availability of treatment drugs are needed.
Related Concept Videos
01:29Bacterial Phylum Chlamydiae
01:26Sexually Transmitted Infections
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...